Table 5.
CISS | TOAST | Total | ||||
---|---|---|---|---|---|---|
LAA | CE | SAO | SOE | SUE | ||
LAA | 77 | 2 | 11 | 0 | 52 | 142 |
LAA-A | 0 | 0 | 0 | 0 | 0 | 0 |
LAA-1 | 34 | 0 | 3 | 0 | 26 | 63 |
LAA-2 | 20 | 1 | 4 | 0 | 17 | 42 |
LAA-3 | 4 | 0 | 1 | 0 | 3 | 8 |
LAA-4 | 19 | 1 | 3 | 0 | 6 | 29 |
CS | 0 | 13 | 0 | 0 | 0 | 13 |
PAD | 1 | 0 | 109 | 0 | 27 | 137 |
OE | 0 | 0 | 0 | 6 | 0 | 6 |
UE | 1 | 0 | 3 | 0 | 18 | 22 |
Total | 79 | 15 | 123 | 6 | 97 | 320 |
CISS Chinese ischemic stroke subclassfication, TOAST trial of Org 10172 in acute stroke treatment, LAA large artery atherosclerosis, LAA-A aortic arch atherosclerosis, LAA-1 parent artery (plaque or thrombus) occluding penetrating artery, LAA-2 artery-to-artery embolism, LAA-3 hypoperfusion/impaired emboli clearance, LAA-4 hypoperfusion/impaired emboli clearance, CS cardiogenic stroke, PAD penetrating artery disease, OE other etiologies, UE undetermined etiology, CE cardioembolism, SAO small-artery occlusion, SOE stroke of other etiologies, SUE stroke of undetermined etiology
k = 0.569